01. Actively Recruiting Clinical Trials
Mesothelioma Clinical Trials Currently Accepting Patients
Mesothelioma patients may consider participating in a clinical trial. Clinical trials are medical studies involving people. There are dozens of active clinical trials recruiting mesothelioma patients who meet the eligibility requirements.
Doctors use mesothelioma clinical studies to evaluate the safety and efficacy of new treatments. If treatments perform well in clinical trials, they can go on to become approved by the U.S. Food and Drug Administration (FDA).
One example of this is the immunotherapy combination of Opdivo® and Yervoy®. Together, these drugs proved successful in clinical trials. Researchers found the combination extended patient survival. Based upon that data, the FDA approved Opdivo® and Yervoy® for the treatment of inoperable pleural mesothelioma.
These important medical studies follow a defined process. Each mesothelioma clinical trial starts with an idea, often in a research laboratory. Treatments that perform well in the lab and in animals can move on to clinical trials testing. This is the point at which researchers allow people to volunteer to help evaluate the new treatment(s).
Mesothelioma patients with limited treatment options may be able to access new treatments through clinical trials. In fact, the American Society of Clinical Oncology (ASCO) recommends clinical trial enrollment for the following pleural mesothelioma patients:
- Patients qualifying for a second round of systemic chemotherapy (second-line) after failure of primary chemotherapy treatment
- Patients with mesothelioma tumors or cells in nearby lymph nodes
- Patients qualifying for pre-surgical or post-surgical radiation therapy
Like all medical treatments, clinical trial participation comes with certain risks. Patients should discuss the potential benefits and risks of enrolling in a clinical trial with their oncologists.
Additional information on clinical trial safety, process, costs and enrollment can be found on our Clinical Trials Overview page.
02. List of Open Clinical Trials
List of Clinical Trials Recruiting Mesothelioma Patients
Provided below is a list of mesothelioma trials that are currently accepting new patients.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Conditions: Mesothelioma
Last Updated: February 5, 2024
Status: Recruiting
Integrated Cancer Repository for Cancer Research (iCaRe2)
Conditions: Mesothelioma
Last Updated: August 9, 2023
Status: Recruiting
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: March 28, 2023
Status: Recruiting
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Conditions: Mesothelioma
Last Updated: March 10, 2023
Status: Recruiting
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Conditions: Mesothelioma
Last Updated: November 1, 2022
Status: Recruiting
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Conditions: Mesothelioma
Last Updated: October 31, 2022
Status: Recruiting
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Conditions: Mesothelioma
Last Updated: October 27, 2022
Status: Recruiting
Rapid Autopsy and Procurement of Cancer Tissue
Conditions: Mesothelioma
Last Updated: October 26, 2022
Status: Recruiting
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: October 25, 2022
Status: Recruiting
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Conditions: Mesothelioma
Last Updated: October 25, 2022
Status: Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: October 24, 2022
Status: Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: October 21, 2022
Status: Recruiting
The Registry of Oncology Outcomes Associated With Testing and Treatment
Conditions: Mesothelioma
Last Updated: October 19, 2022
Status: Recruiting
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Conditions: Mesothelioma
Last Updated: October 18, 2022
Status: Recruiting
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Conditions: Mesothelioma
Last Updated: October 17, 2022
Status: Recruiting
Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance
Conditions: Mesothelioma
Last Updated: October 17, 2022
Status: Recruiting
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Conditions: Mesothelioma
Last Updated: October 13, 2022
Status: Recruiting
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
Conditions: Mesothelioma
Last Updated: October 10, 2022
Status: Recruiting
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: October 10, 2022
Status: Recruiting
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: October 10, 2022
Status: Recruiting
A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: October 7, 2022
Status: Recruiting
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Conditions: Mesothelioma
Last Updated: October 6, 2022
Status: Recruiting
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: October 5, 2022
Status: Recruiting
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Conditions: Mesothelioma
Last Updated: October 5, 2022
Status: Recruiting
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: October 5, 2022
Status: Recruiting
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Conditions: Mesothelioma
Last Updated: September 30, 2022
Status: Recruiting
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 28, 2022
Status: Recruiting
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 28, 2022
Status: Recruiting
Stereotactic Magnetic Resonance Guided Radiation Therapy
Conditions: Mesothelioma
Last Updated: September 27, 2022
Status: Recruiting
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Conditions: Mesothelioma
Last Updated: September 26, 2022
Status: Recruiting
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: September 22, 2022
Status: Recruiting
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Conditions: Mesothelioma
Last Updated: September 15, 2022
Status: Recruiting
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Conditions: Mesothelioma
Last Updated: September 15, 2022
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-I
Conditions: Mesothelioma
Last Updated: September 10, 2022
Status: Recruiting
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 8, 2022
Status: Recruiting
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Conditions: Mesothelioma
Last Updated: September 1, 2022
Status: Recruiting
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Conditions: Mesothelioma
Last Updated: August 26, 2022
Status: Recruiting
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: August 25, 2022
Status: Recruiting
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Conditions: Mesothelioma
Last Updated: August 22, 2022
Status: Recruiting
APG-2449 in Patients With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: August 19, 2022
Status: Recruiting
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Conditions: Mesothelioma
Last Updated: August 17, 2022
Status: Recruiting
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Conditions: Mesothelioma
Last Updated: August 15, 2022
Status: Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Mesothelioma
Last Updated: August 12, 2022
Status: Recruiting
KZR-261 in Subjects With Advanced Solid Malignancies
Conditions: Mesothelioma
Last Updated: August 12, 2022
Status: Recruiting
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Conditions: Mesothelioma
Last Updated: August 10, 2022
Status: Recruiting
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: August 5, 2022
Status: Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Conditions: Mesothelioma
Last Updated: July 27, 2022
Status: Recruiting
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: July 26, 2022
Status: Recruiting
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Conditions: Mesothelioma
Last Updated: July 22, 2022
Status: Recruiting
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: July 22, 2022
Status: Recruiting
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Conditions:
Last Updated: July 22, 2022
Status: Recruiting
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Conditions: Mesothelioma
Last Updated: July 11, 2022
Status: Recruiting
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Conditions:
Last Updated: July 11, 2022
Status: Recruiting
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Conditions: Mesothelioma
Last Updated: June 21, 2022
Status: Recruiting
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Conditions: Mesothelioma
Last Updated: June 16, 2022
Status: Recruiting
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: June 7, 2022
Status: Recruiting
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: June 2, 2022
Status: Recruiting
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: May 27, 2022
Status: Recruiting
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Conditions:
Last Updated: May 20, 2022
Status: Recruiting
Surgery for Mesothelioma After Radiation Therapy Using Exquisite Systemic Therapy
Conditions: Mesothelioma
Last Updated: May 19, 2022
Status: Recruiting
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: May 18, 2022
Status: Recruiting
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
Conditions: Mesothelioma
Last Updated: May 11, 2022
Status: Recruiting
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Conditions: Mesothelioma
Last Updated: May 3, 2022
Status: Recruiting
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Conditions: Mesothelioma
Last Updated: April 15, 2022
Status: Recruiting
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: April 7, 2022
Status: Recruiting
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: April 4, 2022
Status: Recruiting
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Conditions: Mesothelioma
Last Updated: March 23, 2022
Status: Recruiting
CAR T Cells in Mesothelin Expressing Cancers
Conditions: Mesothelioma
Last Updated: March 10, 2022
Status: Recruiting
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Conditions: Mesothelioma
Last Updated: March 4, 2022
Status: Recruiting
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: March 2, 2022
Status: Recruiting
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Conditions: Mesothelioma
Last Updated: February 8, 2022
Status: Recruiting
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
Conditions: Mesothelioma
Last Updated: January 31, 2022
Status: Recruiting
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Conditions: Mesothelioma
Last Updated: January 28, 2022
Status: Recruiting
eRAPID: Online Symptom Reporting in Lung Cancer
Conditions: Mesothelioma
Last Updated: January 27, 2022
Status: Recruiting
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Conditions: Mesothelioma
Last Updated: January 26, 2022
Status: Recruiting
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
Conditions: Mesothelioma
Last Updated: January 24, 2022
Status: Recruiting
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Conditions:
Last Updated: January 14, 2022
Status: Recruiting
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Conditions: Mesothelioma
Last Updated: January 5, 2022
Status: Recruiting
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Conditions: Mesothelioma
Last Updated: December 2, 2021
Status: Recruiting
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
Conditions: Mesothelioma
Last Updated: December 15, 2021
Status: Recruiting
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: December 9, 2021
Status: Recruiting
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Conditions: Mesothelioma
Last Updated: December 8, 2021
Status: Recruiting
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: December 2, 2021
Status: Recruiting
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
Conditions: Mesothelioma
Last Updated: December 2, 2021
Status: Recruiting
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: November 6, 2021
Status: Recruiting
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
Conditions: Mesothelioma
Last Updated: November 4, 2021
Status: Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Conditions: Mesothelioma
Last Updated: November 2, 2021
Status: Recruiting
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Conditions: Mesothelioma
Last Updated: October 15, 2021
Status: Recruiting
UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC
Conditions: Mesothelioma
Last Updated: October 14, 2021
Status: Recruiting
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection
Conditions: Mesothelioma
Last Updated: October 4, 2021
Status: Recruiting
Short Neoadjuvant Hemithoracic IMRT for MPM
Conditions: Mesothelioma
Last Updated: October 4, 2021
Status: Recruiting
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: October 3, 2021
Status: Recruiting
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Conditions:
Last Updated: September 21, 2021
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-II
Conditions: Mesothelioma
Last Updated: September 14, 2021
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-III
Conditions: Mesothelioma
Last Updated: September 14, 2021
Status: Recruiting
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions:
Last Updated: September 13, 2021
Status: Recruiting
Real World Study of MPM in China
Conditions: Mesothelioma
Last Updated: September 13, 2021
Status: Recruiting
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: None
Last Updated: September 13, 2021
Status: Recruiting
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Conditions: Mesothelioma
Last Updated: September 5, 2021
Status: Recruiting
Cardiac MRI Biomarker Testing (GCC 1618)
Conditions: Mesothelioma
Last Updated: August 16, 2021
Status: Recruiting
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Conditions: Mesothelioma
Last Updated: August 13, 2021
Status: Recruiting
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Conditions: Mesothelioma
Last Updated: August 9, 2021
Status: Recruiting
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: July 31, 2021
Status: Recruiting
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Conditions: Mesothelioma
Last Updated: July 23, 2021
Status: Recruiting
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Conditions: Mesothelioma
Last Updated: July 21, 2021
Status: Recruiting
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Conditions: Mesothelioma
Last Updated: July 21, 2021
Status: Recruiting
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: July 19, 2021
Status: Recruiting
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: June 30, 2021
Status: Recruiting
The IMmunotherapy Pleural 5-ALA PDT
Conditions: Mesothelioma
Last Updated: May 18, 2021
Status: Recruiting
Olaparib in Patients With HRD Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: May 12, 2021
Status: Recruiting
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Conditions: Mesothelioma
Last Updated: May 12, 2021
Status: Recruiting
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: April 30, 2021
Status: Recruiting
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Conditions: Mesothelioma
Last Updated: April 30, 2021
Status: Recruiting
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: April 28, 2021
Status: Recruiting
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: April 15, 2021
Status: Recruiting
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: April 12, 2021
Status: Recruiting
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Conditions: Mesothelioma
Last Updated: March 11, 2021
Status: Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Conditions: Mesothelioma
Last Updated: March 8, 2021
Status: Recruiting
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
Conditions: Mesothelioma
Last Updated: March 5, 2021
Status: Recruiting
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Conditions: Mesothelioma
Last Updated: March 2, 2021
Status: Recruiting
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: February 26, 2021
Status: Recruiting
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Conditions: Mesothelioma
Last Updated: February 26, 2021
Status: Recruiting
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Conditions: Mesothelioma
Last Updated: February 25, 2021
Status: Recruiting
DENdritic Cell Immunotherapy for Mesothelioma
Conditions: Mesothelioma
Last Updated: January 27, 2021
Status: Recruiting
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: January 22, 2021
Status: Recruiting
Autologous Dendritic Cell Vaccination in Mesothelioma
Conditions: Mesothelioma
Last Updated: January 19, 2021
Status: Recruiting
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
Conditions: Mesothelioma
Last Updated: July 29, 2020
Status: Recruiting
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: July 28, 2020
Status: Recruiting
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: July 14, 2020
Status: Recruiting
HMPL-453 in Advanced Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: June 16, 2020
Status: Recruiting
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Conditions: Mesothelioma
Last Updated: May 5, 2020
Status: Recruiting
Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed
Conditions: Mesothelioma
Last Updated: December 13, 2019
Status: Recruiting
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Conditions: Mesothelioma
Last Updated: December 11, 2019
Status: Recruiting
Mesothelioma and Radical Surgery 2
Conditions: Mesothelioma
Last Updated: October 28, 2019
Status: Recruiting
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Conditions: Mesothelioma
Last Updated: October 7, 2019
Status: Recruiting
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Conditions: Mesothelioma
Last Updated: November 21, 2016
Status: Recruiting
